Operation Warp Speed Had Trouble Enrolling Patients In COVID-19 Therapeutic Research
US FDA Acting Commissioner Woodcock says there is ‘a long list’ of lessons learned in the OWS therapeutics group, noting trial bureaucracy and the lack of resources and support for community centers.
